ARVN - Arvinas Inc Stock Price, Fair Value and News

33.45USD+0.01 (+0.03%)Market Closed

Market Summary

USD33.45+0.01

Market Closed

0.03%

ARVN Stock Price

View Fullscreen

ARVN RSI Chart

ARVN Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-6.2

Price/Sales (Trailing)

29.01

EV/EBITDA

-5.48

Price/Free Cashflow

-6.49

ARVN Price/Sales (Trailing)

ARVN Profitability

EBT Margin

-463.57%

Return on Equity

-55.65%

Return on Assets

-28.15%

Free Cashflow Yield

-15.4%

ARVN Fundamentals

ARVN Revenue

Revenue (TTM)

78.5M

Rev. Growth (Yr)

4.22%

Rev. Growth (Qtr)

-36.51%

ARVN Earnings

Earnings (TTM)

-367.3M

Earnings Growth (Yr)

-86.73%

Earnings Growth (Qtr)

-141.88%

Breaking Down ARVN Revenue

Last 7 days

-8.9%

Last 30 days

-21.5%

Last 90 days

-8.0%

Trailing 12 Months

22.7%

How does ARVN drawdown profile look like?

ARVN Financial Health

Current Ratio

4.98

Debt/Equity

Debt/Cashflow

-434.75

ARVN Investor Care

Shares Dilution (1Y)

27.81%

Diluted EPS (TTM)

-6.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	137.3M	158.1M	159.4M	78.5M
2022	74.5M	102.8M	126.8M	131.3M
2021	25.2M	24.9M	26.6M	53.5M
2020	45.2M	46.9M	24.5M	25.9M
2019	14.2M	14.8M	41.5M	43.0M
2018	10.0M	11.7M	13.5M	14.3M
2017	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arvinas Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	berkowitz noah	acquired	-	-	63,452	chief medical officer
Feb 23, 2024	peck ronald	acquired	-	-	39,250	chief medical officer
Feb 23, 2024	houston john g	acquired	-	-	124,450	president and ceo
Feb 23, 2024	houston john g	sold	-244,472	47.05	-5,196	president and ceo
Feb 23, 2024	taylor ian	sold	-80,032	47.05	-1,701	chief scientific officer
Feb 23, 2024	cassidy sean a	sold	-80,079	47.05	-1,702	chief financial officer
Feb 23, 2024	taylor ian	acquired	-	-	39,250	chief scientific officer
Feb 23, 2024	loomis david k	acquired	-	-	5,750	chief accounting officer
Feb 23, 2024	peck ronald	sold	-79,938	47.05	-1,699	chief medical officer
Jan 04, 2024	taylor ian	acquired	132,032	16.00	8,252	chief scientific officer

Which funds bought or sold ARVN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	10.89	26,531	263,036	0.01%
Apr 15, 2024	Concurrent Investment Advisors, LLC	new	-	361,015	361,015	0.02%
Apr 05, 2024	CWM, LLC	unchanged	-	-	6,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	7.15	85,618	1,233,530	-%
Apr 05, 2024	GAMMA Investing LLC	added	300	1,112	1,486	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-98.49	-17,610	576	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	new	-	3,045,840	3,045,840	0.01%
Mar 11, 2024	VANGUARD GROUP INC	added	5.28	109,178,000	199,683,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	238	23,298,100	27,121,100	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	523,316	1,004,630	-%

Are Funds Buying or Selling ARVN?

Are funds buying ARVN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARVN

No. of Funds

Unveiling Arvinas Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	5.6%	3,835,364	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.99%	6,800,493	SC 13G/A
Feb 14, 2024	rtw investments, lp	6.2%	4,213,483	SC 13G
Feb 13, 2024	avidity partners management lp	4.4%	2,985,117	SC 13G/A
Feb 13, 2024	vanguard group inc	7.13%	4,851,390	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	5,353,605	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	avidity partners management lp	9.3%	4,950,000	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	4.4%	2,368,130	SC 13G/A
Feb 13, 2023	ecor1 capital, llc	5.9%	3,123,300	SC 13G/A

Recent SEC filings of Arvinas Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	ARS	ARS
Apr 16, 2024	DEF 14A	DEF 14A
Apr 16, 2024	DEFA14A	DEFA14A
Apr 11, 2024	8-K	Current Report
Mar 21, 2024	3	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 19, 2024	3	Insider Trading
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	S-8	Employee Benefits Plan
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to Arvinas Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Arvinas Inc News

Latest updates

Arvinas Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	34,600,000	54,500,000	32,500,000	37,850,000	33,200,000	33,800,000	26,500,000	33,250,000	9,300,000	5,500,000	5,500,000	6,315,915	7,596,776	5,747,681	6,239,628	4,893,273	30,050,227	4,016,489	4,016,489	3,440,165
Operating Expenses	12.6%	122,200,000	108,500,000	129,100,000	120,200,000	113,350,000	97,500,000	99,600,000	84,200,000	80,750,000	56,600,000	57,400,000	47,200,000	45,471,902	39,344,843	32,231,564	29,651,691	27,683,173	24,545,414	22,441,417	19,830,988	20,383,744
S&GA Expenses	19.7%	27,050,000	22,600,000	25,700,000	24,900,000	15,100,000	20,000,000	24,300,000	20,200,000	18,850,000	16,000,000	14,400,000	12,300,000	12,227,596	9,331,925	8,815,474	7,925,005	7,268,390	7,957,364	6,440,779	5,640,629	5,821,445
R&D Expenses	10.8%	95,150,000	85,900,000	103,400,000	95,300,000	98,250,000	77,500,000	75,300,000	64,000,000	61,900,000	40,600,000	43,000,000	34,900,000	33,244,306	30,012,918	23,416,090	21,726,686	20,414,783	16,588,050	16,000,638	14,190,359	14,562,299
EBITDA Margin	-Infinity%	-4.57	-	-1.72	-1.96	-1.86	-1.36	-1.72	-2.39	-3.35	-4.11	-4.41	-4.41	-4.32	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-6,350,000	3,400,000	1,800,000	1,200,000	-1,100,000	300,000	400,000	500,000	51,250	16,250	16,250	16,250	16,250	22,903	22,778	23,638	24,636
Income Taxes	-	1,600,000	-	-300,000	-400,000	10,800,000	2,200,000	3,400,000	4,500,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-139.7%	-153,200,000	-63,900,000	-65,600,000	-81,200,000	-69,250,000	-61,100,000	-64,100,000	-56,600,000	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-164.0%	-4.64	-1.76	-1.75	-2.01	-1.91	-1.45	-1.79	-2.47	-3.44	-4.33	-4.62	-4.58	-	-	-	-	-	-	-	-	-
Net Income	-141.9%	-154,800,000	-64,000,000	-66,600,000	-81,900,000	-82,900,000	-66,200,000	-70,000,000	-63,400,000	-52,950,000	-46,800,000	-50,300,000	-41,000,000	-41,514,424	-30,819,866	-25,226,539	-21,739,171	-21,047,716	-17,675,373	-17,164,646	-14,404,492	-16,087,866
Net Income Margin	-152.6%	-4.68	-1.85	-1.88	-2.19	-2.15	-1.99	-2.27	-2.86	-3.57	-6.75	-6.57	-5.51	-	-	-	-	-	-	-	-	-
Free Cashflow	3.1%	-83,200,000	-85,900,000	-89,300,000	-92,300,000	-72,300,000	-68,800,000	-80,000,000	-59,200,000	-37,600,000	680,200,000	-47,900,000	-40,000,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	23.3%	1,305	1,058	1,084	1,176	1,269	1,335	1,407	1,488	1,582	1,605	644	682	717	272	263	282	302	209	172	187	199
Current Assets	23.9%	1,280	1,033	1,057	1,148	1,240	1,305	1,376	1,457	1,553	1,576	628	665	703	258	250	270	291	200	163	180	196
Cash Equivalents	174.1%	312	114	91.00	130	81.00	133	93.00	62.00	108	260	53.00	346	588	89.00	22.00	36.00	9.00	12.00	11.00	29.00	3.00
Net PPE	-9.4%	12.00	13.00	13.00	13.00	13.00	14.00	14.00	13.00	13.00	12.00	12.00	12.00	12.00	12.00	11.00	10.00	8.00	7.00	6.00	4.00	4.00
Liabilities	7.2%	645	601	620	665	704	713	736	765	800	787	61.00	66.00	75.00	67.00	65.00	71.00	75.00	75.00	56.00	59.00	63.00
Current Liabilities	-19.0%	257	317	307	283	295	245	238	238	262	183	42.00	40.00	49.00	40.00	34.00	33.00	33.00	29.00	21.00	21.00	23.00
Long Term Debt	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
LT Debt, Current	-100.0%	-	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
LT Debt, Non Current	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	44.4%	660	457	464	511	565	622	671	723	782	818	583	615	642	205	198	212	227	134	117	128	137
Retained Earnings	-13.1%	-1,332	-1,177	-1,113	-1,047	-965	-882	-816	-746	-682	-629	-583	-532	-491	-450	-419	-394	-372	-351	-333	-316	-302
Additional Paid-In Capital	21.4%	1,996	1,644	1,590	1,571	1,549	1,529	1,509	1,488	1,469	1,448	1,167	1,148	1,134	654	616	607	599	485	450	444	439
Shares Outstanding	23.6%	68.00	55.00	53.00	53.00	53.00	53.00	53.00	53.00	50.00	50.00	49.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,293	-	-	-	2,176	-	-	-	3,457	-	-	-	1,348	-	-	-	465	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	2.0%	-83,100	-84,800	-88,700	-91,200	-71,200	-66,600	-78,600	-57,100	-35,700	681,500	-47,400	-39,000	-28,964	-22,383	-21,401	-16,949	-16,152	1,854	-13,569	-12,732	-12,254
Share Based Compensation	0%	16,700	16,700	18,300	19,900	20,100	18,800	20,000	16,600	17,000	15,200	14,600	10,300	8,078	8,247	7,755	6,120	5,009	4,601	5,313	5,177	5,441
Cashflow From Investing	-176.7%	-53,700	70,000	48,600	138,600	19,400	105,800	109,000	8,600	-115,600	-741,100	-249,100	-207,800	56,912	59,283	5,610	42,495	-95,431	-31,814	-4,228	38,374	-101,861
Cashflow From Financing	783.4%	334,800	37,900	500	1,500	500	1,200	500	2,500	3,900	266,600	3,600	4,500	471,475	30,496	1,279	1,350	108,638	30,754	353	-45.54	111,115

ARVN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations
Revenue	$ 78.5	$ 131.4	$ 53.6
Operating expenses:
Research and development	379.7	315.0	180.4
General and administrative	100.3	79.6	61.6
Total operating expenses	480.0	394.6	242.0
Loss from operations	(401.5)	(263.2)	(188.4)
Other income (expense)
Other (expense) income, net	(1.2)	0.2	2.5
Interest income, net	38.8	12.0	1.8
Total other income	37.6	12.2	4.3
Net loss before income taxes and loss from equity method investment	(363.9)	(251.0)	(184.1)
Income tax expense	(0.9)	(20.9)	0.0
Loss from equity method investment	(2.5)	(10.6)	(6.9)
Net loss	$ (367.3)	$ (282.5)	$ (191.0)
Net loss per common share - basic (in usd per share)	$ (6.62)	$ (5.31)	$ (3.82)
Net loss per common share - diluted (in usd per share)	$ (6.62)	$ (5.31)	$ (3.82)
Weighted-average common shares outstanding - basic (in shares)	55.5	53.2	50.0
Weighted-average common shares outstanding - diluted (in shares)	55.5	53.2	50.0
Consolidated Statements of Comprehensive Loss
Net loss	$ (367.3)	$ (282.5)	$ (191.0)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities	16.1	(14.5)	(5.2)
Comprehensive loss	$ (351.2)	$ (297.0)	$ (196.2)

ARVN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 311,700,000	$ 81,300,000
Restricted cash	5,500,000	5,500,000
Marketable securities	949,300,000	1,124,000,000
Accounts receivable	0	1,000,000.0
Other receivables	7,200,000	7,000,000.0
Prepaid expenses and other current assets	6,500,000	21,400,000
Total current assets	1,280,200,000	1,240,200,000
Property, equipment and leasehold improvements, net	11,500,000	13,400,000
Operating lease right of use assets	2,500,000	4,400,000
Collaboration contract asset and other assets	10,400,000	10,800,000
Total assets	1,304,600,000	1,268,800,000
Current liabilities:
Accounts payable and accrued liabilities	92,200,000	74,700,000
Deferred revenue	163,000,000.0	218,600,000
Current portion of operating lease liability	1,900,000	1,800,000
Total current liabilities	257,100,000	295,100,000
Deferred revenue	386,200,000	405,100,000
Long term debt	800,000	1,000,000.0
Operating lease liability	500,000	2,700,000
Total liabilities	644,600,000	703,900,000
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value, zero shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock, $0.001 par value, 68.0 and 53.2 shares issued and outstanding as of December 31, 2023 and 2022, respectively	100,000	100,000
Accumulated deficit	(1,332,700,000)	(965,400,000)
Additional paid-in capital	1,995,700,000	1,549,400,000
Accumulated other comprehensive loss	(3,100,000)	(19,200,000)
Total stockholders' equity	660,000,000.0	564,900,000
Total liabilities and stockholders' equity	$ 1,304,600,000	$ 1,268,800,000

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

CEO	Dr. John G. Houston Ph.D.
WEBSITE	arvinas.com
INDUSTRY	Biotechnology
EMPLOYEES	415

Arvinas Inc Frequently Asked Questions

What is the ticker symbol for Arvinas Inc? What does ARVN stand for in stocks?

ARVN is the stock ticker symbol of Arvinas Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arvinas Inc (ARVN)?

As of Wed Apr 17 2024, market cap of Arvinas Inc is 2.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARVN stock?

You can check ARVN's fair value in chart for subscribers.

What is the fair value of ARVN stock?

You can check ARVN's fair value in chart for subscribers. The fair value of Arvinas Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arvinas Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arvinas Inc a good stock to buy?

The fair value guage provides a quick view whether ARVN is over valued or under valued. Whether Arvinas Inc is cheap or expensive depends on the assumptions which impact Arvinas Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARVN.

What is Arvinas Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, ARVN's PE ratio (Price to Earnings) is -6.2 and Price to Sales (PS) ratio is 29.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARVN PE ratio will change depending on the future growth rate expectations of investors.